CSE’s Barrington Miller was recently joined by Christopher Moreau, CEO of Algernon Pharmaceuticals Inc. (CSE:AGN), to discuss his company’s work to develop NP-120 (Ifenprodil) as a new therapeutic in the fight against COVID-19.
In this discussion, Chris outlines how his company focuses on drug re-purposing, a term that is widely understood through the example provided by Viagra (1:04), the important distinction between therapeutic treatments and anti-virals and vaccines (12:14), and why the “grandaddy” of all market approvals is from the USFDA (18:25).
Listen until the end to hear how the company’s name is actually inspired by the title of a science fiction novel, and how the company has a history of investigating compounds developed by the Soviet Union!
(Subsequent to this chat, Algernon announced Health Canada approval to move forward with its PH2b/3 trial here with Ifenprodil as a potential treatment for COVID-19.)
Related Link
algernonpharmaceuticals.com